Psoriasis/Psoriatic Arthritis Patients’ Long-term Treatment Patterns and Adherence to Systemic Treatments Monitoring Recommendations
DOI:
https://doi.org/10.2340/actadv.v103.6505Keywords:
guideline concordance, monitoring, treatment patterns, Adherence, persistence, psoriasisAbstract
Limited information exists regarding treatment of patients with psoriasis/psoriatic arthritis in primary care. The aim of this study is to assess treatment patterns, adherence, persistence, and compliance in newly diagnosed patients with psoriasis/psoriatic arthritis from 2012 to 2018 in Stockholm, Sweden. In addition, laboratory monitoring before initiation of treatment and at recommended intervals was quantified for patients prescribed methotrexate or biologics. A total of 51,639 individuals were included, with 39% initiating treatment with topical corticosteroids and < 5% receiving systemic treatment within 6 months post-diagnosis. During a median (interquartile range) follow-up of 7 (4–8) years, 18% of patients received systemic treatments at some point. Overall, 5-year persistence rates were 32%, 45% and 19% for methotrexate, biologics, and other systemic treatments, respectively. Pre-initiation laboratory tests, as recommended by guidelines, were performed in approximately 70% and 62% of methotrexate and biologics users, respectively. Follow-up monitoring at recommended time intervals occurred in 14–20% and 31–33% of patients prescribed methotrexate and biologics, respectively. These findings highlight gaps in the pharmacological care of patients with psoriasis/psoriatic arthritis, including suboptimal adherence/persistence and inadequate laboratory monitoring.
Downloads
References
Svensson Å SO, Thalme T, Schmitt-Egenholf M, Alenius G-M. Läkemedelsbehandling av psoriasis och psoriasisartrit-bakgrundsdokument. Läkemedelsverket, 2019: p. 34-35.
Van den Bosch F, Coates L. Clinical management of psoriatic arthritis. Lancet 2018; 391: 2285-2294.
https://doi.org/10.1016/S0140-6736(18)30949-8 DOI: https://doi.org/10.1016/S0140-6736(18)30949-8
World Health Organisation (2014) Resolution on psoriasis (WHA 67.9) by the Sixty-Seventh World Assembly of the World Health Organization, Available from https://apps.who.int/gb/ebwha/pdf_files/WHA67/A67_R9-en.pdf
Ingrasciotta Y, Isgrò V, Ientile V, Tari M, Trifirò G, Guarneri C. Are patients with psoriasis and psoriatic arthritis undertreated? A population-based study from southern Italy. J Clin Med 2021; 10: 3431.
https://doi.org/10.3390/jcm10153431 DOI: https://doi.org/10.3390/jcm10153431
Perrone V, Losi S, Filippi E, Mezzetti M, Dovizio M, Sangiorgi D, et al. Analysis of the pharmacoutilization of biological drugs in psoriatic arthritis patients: a real-world retrospective study among an Italian population. Rheumatol Ther 2022; 9: 875-890.
https://doi.org/10.1007/s40744-022-00440-1 DOI: https://doi.org/10.1007/s40744-022-00440-1
Warren RB, Smith CH, Yiu ZZN, Ashcroft DM, Barker J, Burden AD, et al. Differential drug survival of biologic therapies for the treatment of psoriasis: a prospective observational cohort study from the British Association of Dermatologists Biologic Interventions Register (BADBIR). J Invest Dermatol 2015; 135: 2632-2640.
https://doi.org/10.1038/jid.2015.208 DOI: https://doi.org/10.1038/jid.2015.208
Schmitt-Egenolf M, Freilich J, Stelmaszuk-Zadykowicz NM, Apol E, Hansen JB, Levin L. Drug persistence of biologic treatments in psoriasis: a Swedish national population study. Dermatol Ther (Heidelb) 2021; 11: 2107-2121.
https://doi.org/10.1007/s13555-021-00616-7 DOI: https://doi.org/10.1007/s13555-021-00616-7
Calara PS, Althin R, Carlsson KS, Schmitt-Egenolf M. Regional differences in the prescription of biologics for psoriasis in Sweden: a register-based study of 4168 patients. BioDrugs 2017; 31: 75-82.
https://doi.org/10.1007/s40259-016-0209-y DOI: https://doi.org/10.1007/s40259-016-0209-y
Svedbom A, Dalén J, Mamolo C, Cappelleri JC, Petersson IF, Ståhle M. Treatment patterns with topicals, traditional systemics and biologics in psoriasis - a Swedish database analysis. J Eur Acad Dermatol Venereol 2015; 29: 215-223.
https://doi.org/10.1111/jdv.12494 DOI: https://doi.org/10.1111/jdv.12494
Tveit KS, Duvetorp A, Østergaard M, Skov L, Danielsen K, Iversen L, et al. Treatment use and satisfaction among patients with psoriasis and psoriatic arthritis: results from the NORdic PAtient survey of Psoriasis and Psoriatic arthritis (NORPAPP). J Eur Acad Dermatol Venereol 2019; 33: 340-354.
https://doi.org/10.1111/jdv.15252 DOI: https://doi.org/10.1111/jdv.15252
Calara PS, Norlin JM, Althin R, Carlsson KS, Schmitt-Egenolf M. Healthcare provider type and switch to biologics in psoriasis: evidence from real-world practice. BioDrugs 2016; 30: 145-151.
https://doi.org/10.1007/s40259-016-0163-8 DOI: https://doi.org/10.1007/s40259-016-0163-8
Norlin JM, Steen Carlsson K, Persson U, Schmitt-Egenolf M. Resource use in patients with psoriasis after the introduction of biologics in Sweden. Acta Derm Venereol 2015; 95: 156-161.
https://doi.org/10.2340/00015555-1895 DOI: https://doi.org/10.2340/00015555-1895
Nast A, Smith C, Spuls PI, Avila Valle G, Bata-Csörgö Z, Boonen H, et al. EuroGuiDerm Guideline on the systemic treatment of Psoriasis vulgaris - Part 1: treatment and monitoring recommendations. J Eur Acad Dermatol Venereol 2020; 34: 2461-2498.
https://doi.org/10.1111/jdv.16915 DOI: https://doi.org/10.1111/jdv.16915
Carrero JJ, Elinder CG. The Stockholm CREAtinine Measurements (SCREAM) project: Fostering improvements in chronic kidney disease care. J Intern Med 2022; 291: 254-268.
https://doi.org/10.1111/joim.13418 DOI: https://doi.org/10.1111/joim.13418
The National Board of Health and Welfare. National guidelines for psoriasis care: Support for governance and management. 2019 [accessed Jan 31, 2022]. Available from: https://www.socialstyrelsen.se/regler-och-riktlinjer/nationella-riktlinjer/riktlinjer-och-utvarderingar/psoriasis/
National Board of Health and Welfare, Läkemedelsregistret. 2021. [accessed 2022 Jan 31]. Available from: https://www.socialstyrelsen.se/statistik-och-data/register/lakemedelsregistret/
Stockholm County County Council. VAL-databaserna. 2022. [accessed 2022 Jan 31]. Available from: https://www.folkhalsokollen.se/datakallor/val-databaserna/
Karve S, Cleves MA, Helm M, Hudson TJ, West DS, Martin BC. Good and poor adherence: optimal cut-point for adherence measures using administrative claims data. Curr Med Res Opin 2009; 25: 2303-2310.
https://doi.org/10.1185/03007990903126833 DOI: https://doi.org/10.1185/03007990903126833
The Swedish Society for Dermatology and Venereology (SSDV). [SSDV:s behandlingsrekommendationer för systemisk behandling av psoriasis]. 2022. [accessed Jan 31, 2022] Available from: https://www.ssdv.se/images/SSDVs_behandlingsrekommendationer_for_systemisk_behandli_ng_av_psoriasis_2022-05-25.pdf.
Armstrong AW, Robertson AD, Wu J, Schupp C, Lebwohl MG. Undertreatment, treatment trends, and treatment dissatisfaction among patients with psoriasis and psoriatic arthritis in the United States: findings from the National Psoriasis Foundation Surveys, 2003-2011. JAMA Dermatol 2013; 149: 1180-1185.
https://doi.org/10.1001/jamadermatol.2013.5264 DOI: https://doi.org/10.1001/jamadermatol.2013.5264
Lambert J, Ghislain P-D, Lambert J, Cauwe B, Van den Enden M. Treatment patterns in moderate-to-severe plaque psoriasis: results from a Belgian cross-sectional study (DISCOVER). J Dermatolog Treat 2017; 28: 394-400.
https://doi.org/10.1080/09546634.2016.1255304 DOI: https://doi.org/10.1080/09546634.2016.1255304
Muddasani S, Fleischer AB, Jr., Feldman SR. Treatment practices for psoriasis and how they are changing. J Am Acad Dermatol 2021; 84: 579-581.
https://doi.org/10.1016/j.jaad.2020.09.064 DOI: https://doi.org/10.1016/j.jaad.2020.09.064
Do MH, Schwartz Z, Abedian S, Lipner SR. Trends in psoriasis treatment 2005 to 2018: Declining phototherapy utilization and concomitant increased use of biologics. Dermatol Ther 2020; 33: e14276.
https://doi.org/10.1111/dth.14276 DOI: https://doi.org/10.1111/dth.14276
Shaw MK, Davis SA, Feldman SR, Fleischer AB, Jr. Trends in systemic psoriasis treatment therapies from 1993 through 2010. J Drugs Dermatol 2014; 13: 917-920.
Singh P, Silverberg JI. Real-world trends in biologic, oral systemic, and phototherapy in US patients with psoriasis or psoriatic arthritis. J Am Acad Dermatol 2020; 83: 256-257.
https://doi.org/10.1016/j.jaad.2020.01.045 DOI: https://doi.org/10.1016/j.jaad.2020.01.045
Hiremath AC, Bhandari R, Wali S, Ganachari MS, Doshi B. Impact of clinical pharmacist on medication adherence among psoriasis patients: a randomized controlled study. Clin Epidemiol Glob Health 2021; 10: 100687.
https://doi.org/10.1016/j.cegh.2020.100687 DOI: https://doi.org/10.1016/j.cegh.2020.100687
Cline A, Unrue EL, Cardwell LA, Alinia H, Tull R, Feldman SR, et al. Internet-based survey intervention improves adherence to methotrexate among psoriasis patients. J Dermatolog Treat 2022; 33: 2784-2789.
https://doi.org/10.1080/09546634.2022.2071821 DOI: https://doi.org/10.1080/09546634.2022.2071821
Svendsen MT, Andersen F, Andersen KH, Pottegård A, Johannessen H, Möller S, et al. A smartphone application supporting patients with psoriasis improves adherence to topical treatment: a randomized controlled trial. Br J Dermatol 2018; 179: 1062-1071.
https://doi.org/10.1111/bjd.16667 DOI: https://doi.org/10.1111/bjd.16667
Piragine E, Petri D, Martelli A, Janowska A, Dini V, Romanelli M, et al. Adherence and persistence to biological drugs for psoriasis: systematic review with meta-analysis. J Clin Med 2022; 11: 1506.
https://doi.org/10.3390/jcm11061506 DOI: https://doi.org/10.3390/jcm11061506
Mourad AI, Gniadecki R. Biologic drug survival in psoriasis: a systematic review & comparative meta-analysis. Front Med 2021; 7: 625755.
https://doi.org/10.3389/fmed.2020.625755 DOI: https://doi.org/10.3389/fmed.2020.625755
Raaby L, Zachariae C, Østensen M, Heickendorff L, Thielsen P, Grønbæk H, et al. Methotrexate use and monitoring in patients with psoriasis: a consensus report based on a Danish expert meeting. Acta Derm Venereol 2017; 97: 426-432.
https://doi.org/10.2340/00015555-2599 DOI: https://doi.org/10.2340/00015555-2599
Sierocinski E, Angelow A, Mainz A, Walker J, Chenot J-F. Patientensicherheit in der Rheumatherapie. Z fur Rheumatol 2021; 80: 418-424.
https://doi.org/10.1007/s00393-021-00976-7 DOI: https://doi.org/10.1007/s00393-021-00976-7
Fraser SD, Lin SX, Stammers M, Culliford D, Ibrahim K, Barrett R, et al. Persistently normal blood tests in patients taking methotrexate for RA or azathioprine for IBD: a retrospective cohort study. Br J Gen Pract 2022; 72: e528-e537.
https://doi.org/10.3399/BJGP.2021.0595 DOI: https://doi.org/10.3399/BJGP.2021.0595
Mazaud C, Fardet L. Daily practices regarding safety monitoring of low-dose methotrexate and comparison to guidelines: a population-based cohort study. Therapie 2021; 76: 425-433.
https://doi.org/10.1016/j.therap.2019.05.004 DOI: https://doi.org/10.1016/j.therap.2019.05.004
Additional Files
Published
How to Cite
Issue
Section
Categories
License
Copyright (c) 2023 Åsa Krantz, Juan Jesus Carrero, Yuanhang Yang, Lovisa Schalin, Josefin Lysell, Faizan Mazhar
This work is licensed under a Creative Commons Attribution 4.0 International License.
All digitalized ActaDV contents is available freely online. The Society for Publication of Acta Dermato-Venereologica owns the copyright for all material published until volume 88 (2008) and as from volume 89 (2009) the journal has been published fully Open Access, meaning the authors retain copyright to their work.
Unless otherwise specified, all Open Access articles are published under CC-BY-NC licences, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material for non-commercial purposes, provided proper attribution to the original work.
